JW Shinyak Signs Exclusive Domestic Sales Agreement with Galderma Korea for Hair Loss and Onychomycosis Treatments

JW Shinyak announced on the 15th that it has signed an exclusive domestic sales contract with Galderma Korea for the hair loss treatment 'L-Kranell Alpha Solution (active ingredient: Alpatradilol)' and the nail fungus treatment 'Loceryl Nail Lacquer (active ingredient: Amorolfine)'.

Kim Yong-gwan, CEO of JW Shinyak (right), and Kim Yeon-hee, CEO of Galderma Korea, are posing for a commemorative photo after signing the contract.
[Photo by JW Shinyak]

Under the contract, JW Shinyak will be solely responsible for domestic sales and marketing of these products from Galderma Korea.

L-Kranell Alpha Solution is an androgenic alopecia treatment suitable for both men and women. It minimizes hair loss by triple inhibiting the production of dihydrotestosterone, the cause of hair loss. It is a once-daily treatment that can be easily applied to the scalp using an applicator, enhancing convenience.

Clinical results involving 51 female patients with androgenic alopecia in Korea showed that after 8 months of application, hair count increased by 9.8%, and hair thickness increased by 13.2%. Additionally, over 80% of clinical participants evaluated the product as "easy to apply and non-sticky on the scalp and hair."

Loceryl Nail Lacquer, the first product Galderma Korea launched domestically in 1999, is the world's best-selling topical treatment for onychomycosis (nail fungus). It is a nail polish-type topical agent applied directly to the nails, maintaining antifungal effects for 7 to 14 days with only 1 to 2 applications per week. JW Shinyak explains that it is rapidly absorbed into the nails, is not easily washed away by water or sweat, and forms a protective film on the surface, effectively preventing infection transmission.

JW Shinyak plans to further strengthen its competitiveness in the domestic dermatological treatment market through this contract. Kim Yong-gwan, CEO of JW Shinyak, said, "With the introduction of Galderma products proven excellent in the global market, we have established a diverse lineup alongside our existing in-house pharmaceuticals. Based on our marketing capabilities in the clinic market, we will nurture Galderma products into blockbusters."